Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study.

MLA

Yamashita, Shizuya, et al. “Clinical Pharmacology of Pemafibrate Extended-Release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-Controlled, Randomized, Single-Blind, Crossover Study.” Journal of Atherosclerosis and Thrombosis, Sept. 2024. EBSCOhost, https://doi.org/10.5551/jat.65001.

APA

Yamashita, S., Araki, E., Arai, H., Yokote, K., Tanigawa, R., Saito, A., Suganami, H., Minamikawa, S., & Ishibashi, S. (2024). Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.65001

Chicago

Yamashita, Shizuya, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Hideki Suganami, Sara Minamikawa, and Shun Ishibashi. 2024. “Clinical Pharmacology of Pemafibrate Extended-Release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-Controlled, Randomized, Single-Blind, Crossover Study.” Journal of Atherosclerosis and Thrombosis, September. doi:10.5551/jat.65001.